CE Mark Approval Granted for Cerenovus' Bravo Flow Diverter to Treat Intracranial Aneurysms

 

August 8, 2018—Cerenovus, part of the Johnson & Johnson Medical Devices Companies, announced it has received European CE Mark approval for the Bravo flow diverter for use in the treatment of intracranial aneurysms. Early evaluations are scheduled to take place across Europe ahead of European commercialization.

The Bravo device is designed to improve clinician ease of use, improve cost effectiveness, and reduce length of procedure. The device is currently not approved for use in the United States.

Professor Patrick Brouwer, MD, commented in the company's announcement, “Flow diverters are now widely used and for many, have become the go to option for the treatment of complex aneurysms. I believe the design of the Bravo flow diverter, particularly the proximal and distal expansion rings, provides a fresh approach to treat aneurysms.” Prof. Brouwer is Senior Consultant Neurointerventionalist at Karolinska University Hospital in Stockholm, Sweden.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.